A new paradigm of RNA-targeting therapeutics

Nucyrna’s oligonucleotide platform can target both Nuclear & Cytoplasmic RNA, enabling unique RNA-targeting capacities for addressing complex pathology.





Our technology has demonstrated a remarkable therapeutic index profile in CNS and we are focusing on neurodegenerative diseases.

Leadership team

Damon (Feng) Wang, PhD

CEO, co-founder

Joseph Klim, PhD

Director of Neuroscience, co-founder

Scientific founders & advisors

Jonathan Watts, PhD

co-founder & advisor

Robert Brown, MD, DPhil

co-founder & advisor

Evangelos Kiskinis, PhD

co-founder & advisor